Neuroblastoma Clinical Trials

114 recruitingLast updated: June 17, 2026

There are 114 actively recruiting neuroblastoma clinical trials across 40 countries. Studies span Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Neuroblastoma Trials at a Glance

114 actively recruiting trials for neuroblastoma are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Phase 1 with 46 trials, with the heaviest enrollment activity in New York, Boston, and Philadelphia. Lead sponsors running neuroblastoma studies include National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and Giselle Sholler.

Browse neuroblastoma trials by phase

Treatments under study

About Neuroblastoma Clinical Trials

Looking for clinical trials for Neuroblastoma? There are currently 78 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 114 trials

Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Endocrine TumorsNeuroblastomaThyroid Neoplasms+2 more
National Cancer Institute (NCI)2,415 enrolled1 locationNCT01005654
Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Nasopharyngeal CarcinomaKidney CancersEsthesioneuroblastoma+7 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 2

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium62 enrolled13 locationsNCT06450041
Recruiting
Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

NeuroblastomaPineoblastomaAtypical Teratoid/Rhabdoid Tumor+11 more
C17 Council15 enrolled12 locationsNCT06942039
Recruiting
Phase 2

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NeuroblastomaHigh Risk NeuroblastomaMetastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center94 enrolled7 locationsNCT06057948
Recruiting
Phase 1Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Diffuse Large B Cell LymphomaEwing SarcomaNeuroblastoma+2 more
Merck Sharp & Dohme LLC90 enrolled70 locationsNCT06395103
Recruiting
Phase 2

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

Neuroblastoma
Children's Hospital Medical Center, Cincinnati20 enrolled1 locationNCT07635056
Recruiting
Phase 2

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma Recurrent
St. Jude Children's Research Hospital54 enrolled4 locationsNCT07085338
Recruiting
Phase 2

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

Neuroblastoma (NB)Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital27 enrolled1 locationNCT07318831
Recruiting
Phase 2

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI)40 enrolled1 locationNCT06176989
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

EsthesioneuroblastomaOlfactory Neuroblastoma
National Cancer Institute (NCI)525 enrolled1 locationNCT04755205
Recruiting
Phase 2

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

PheochromocytomaNeuroblastoma
Memorial Sloan Kettering Cancer Center200 enrolled1 locationNCT00107289
Recruiting
Phase 2

68Ga-DOTATATE Neuroblastoma Imaging Pilot

Neuroblastoma
Centre de recherche du Centre hospitalier universitaire de Sherbrooke20 enrolled3 locationsNCT04559217
Recruiting
Phase 1

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Neuroblastoma
National Cancer Institute (NCI)40 enrolled1 locationNCT06995872
Recruiting
Phase 1

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Ewing SarcomaNeuroblastomaRhabdomyosarcoma+1 more
Children's National Research Institute18 enrolled2 locationsNCT07172958